Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. While there are positives like improved EBITDA, cost reductions, and strong cash position, there are concerns about macroeconomic uncertainties, execution risks in new markets, and a reduction in biosecurity guidance. The Q&A section reveals potential in automation and RNA solutions but lacks clarity on timelines and geopolitical impacts. Overall, the mixed signals and lack of strong catalysts suggest a neutral stock price movement in the short term.
Key Financial Performance
Cell Engineering revenue $39 million in Q2 2025, up 8% compared to Q2 2024. The increase was driven by supporting a total of 120 revenue-generating programs, representing a 10% increase year-over-year.
Biosecurity revenue $10 million in Q2 2025 at a segment gross margin of 18%. The segment gross margin excludes stock-based compensation.
Cell Engineering R&D expenses Decreased 63% from $84 million in Q2 2024 to $31 million in Q2 2025. This decrease was driven by restructuring efforts.
Cell Engineering G&A expenses Decreased 57% from $33 million in Q2 2024 to $14 million in Q2 2025. This decrease was driven by restructuring efforts.
Total adjusted EBITDA Negative $28 million in Q2 2025, improved from negative $99 million in Q2 2024, a 72% improvement. The improvement was due to cost reductions and restructuring.
Cash burn $38 million in Q2 2025, down from $110 million in Q2 2024. The significant decrease was a direct result of restructuring efforts.
Cash and cash equivalents $474 million with no bank debt as of Q2 2025. This provides a margin of safety and strategic flexibility.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Automation and Datapoints: Ginkgo is expanding into life science tools with automation and datapoints offerings. They have developed reconfigurable automation carts and software to address gaps in the market, enabling high-throughput, scalable lab operations. This includes a new automated anaerobic system for Pacific Northwest National Labs.
Reagents: Launched a new reagent product, a cell-free protein synthesis kit, offering twice the yield at half the cost compared to market leaders. The product is priced at $2,000 for a 10 ml kit and has gained traction in the academic research market.
Expansion into Life Science Tools: Ginkgo is transitioning from an R&D solutions business to a life science tools provider, targeting new markets such as academic research and CRO services.
Cost Reduction: Achieved $250 million annual run rate cost savings a quarter ahead of schedule, reducing cash burn to $38 million in Q2 2025 from $110 million in Q2 2024.
Revenue Growth: Cell Engineering revenue increased by 8% year-over-year to $39 million in Q2 2025, with a 10% increase in revenue-generating programs. Biosecurity revenue was $10 million with an 18% gross margin.
Strategic Shift to Life Science Tools: The company is focusing on automation, AI-enabled science, and reagents to drive growth into 2026, leveraging its expertise in high-throughput and scalable lab operations.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Adjusted EBITDA breakeven target: The company aims to reach adjusted EBITDA breakeven by the end of 2026, but this goal is contingent on maintaining cost reductions and cash margin of safety. Any failure to sustain these efforts could jeopardize financial stability.
Cost-cutting measures: While the company achieved $250 million in annual run rate cost savings ahead of schedule, these measures were described as 'painful,' indicating potential risks to employee morale, operational efficiency, or long-term growth.
Cash burn and financial health: Although cash burn has decreased significantly, it remains a concern. The company has $474 million in cash and no bank debt, but any unexpected financial strain could force unfavorable capital market engagements.
Automation and AI investments: The company is heavily investing in automation and AI to scale operations and reduce costs. However, these initiatives are capital-intensive and may not yield immediate returns, posing a risk to short-term financial performance.
Biosecurity revenue and margins: Biosecurity revenue was $10 million with a segment gross margin of 18%, which is relatively low. This could indicate challenges in scaling this segment profitably.
Excess lease space costs: The company incurred $12 million in costs related to excess lease space, which is a cash operating cost not contributing to revenue. This could be a drag on profitability if not mitigated through subleasing.
Competitive pressures: The company faces competition from biotech firms in China offering lower-cost labor and infrastructure, which could pressure Ginkgo's pricing and market share.
Regulatory and macroeconomic uncertainties: The company acknowledged navigating continued uncertainty in the macro environment, which could impact operations and financial performance.
Expansion into life science tools: The company is transitioning from R&D solutions to life science tools, a move that involves entering new markets and competing with established players, posing execution risks.
Reagent product launch: The company launched its first reagent product, but its success depends on market adoption, particularly in the academic research market, which is new territory for Ginkgo.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: The company reaffirms its total revenue guidance for 2025, projecting a range of $167 million to $187 million. Cell Engineering revenue is expected to be between $117 million and $137 million, while Biosecurity revenue is anticipated to be at least $40 million.
Adjusted EBITDA Breakeven Target: The company aims to achieve adjusted EBITDA breakeven by the end of 2026.
Cost Management and Cash Position: The company has achieved its $250 million annual run rate cost savings target a quarter early, maintaining a cash margin of safety with $474 million in cash and cash equivalents and no bank debt. This positions the company to strategically engage with capital markets and focus on growth initiatives.
Expansion into Life Science Tools: The company is transitioning from an R&D solutions business to the life science tools space, with a focus on automation, datapoints, and reagents. This includes launching new products and services aimed at improving scalability and efficiency in research and development.
Automation and AI-Enabled Science: The company is investing in automation technologies to create scalable, high-throughput research solutions. This includes reconfigurable automation carts and software to enable AI-driven science, with plans to expand these offerings significantly in the future.
New Product Launches: The company has launched its first reagent product, a cell-free protein synthesis kit, targeting both commercial and academic research markets. Early sales and sample requests indicate strong interest.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Is Ginkgo Automation expected to become a primary driver of the company's revenue? Is Ginkgo considering acquiring additional companies in the near future? What is the strategic significance of Ginkgo RNA solutions for the company?
A:Jason Kelly stated that automation is expected to be a significant part of Ginkgo's future business, potentially becoming the majority of the company's revenue if it achieves general-purpose automation akin to a lab bench. Regarding acquisitions, there are no immediate plans, but the company remains open to opportunities if a good fit arises. On RNA solutions, Ginkgo is leveraging its expertise to offer services like RNA discovery, turning capabilities into off-the-shelf services, and expects more developments in this area.
Q:Could you provide more details about your ADME data generation software? Are you planning to develop your own models on the generated ADME data? How does the meter beat pricing work in terms of licensing over a contract's lifetime? Are you pushing the service to partners with their own RAC systems?
A:Jason Kelly explained that Ginkgo demonstrates capabilities through service offerings on RAC hardware and can install these systems at customer sites if needed. The meter beat pricing aims to match overseas CRO service costs, ensuring competitive pricing in the U.S. Regarding ADME data, Ginkgo focuses on generating data for customers rather than developing standalone AI models, though it releases data sets for external use. The company is open to enabling others to create models using its data.
Q:On the lower biosecurity guide, are there any areas particularly exposed to geopolitical pullback or tensions? Are there specific end markets seeing exposure?
A:Jason Kelly noted a reduction in biosecurity guidance due to delays in international contracts. While not entirely off the table, the company is being conservative. He highlighted a growing U.S. focus on defense technology and biodefense, positioning Ginkgo's biosecurity business to adapt to market developments.
Q:Regarding your target of adjusted EBITDA profitability next year, what are the key levers to bridge the gap from today? Where do you see the most significant impact coming from?
A:Steven P. Coen highlighted cost reductions of $250 million over the past four quarters, with further opportunities for cost savings and revenue growth. Key revenue drivers include contributions from solutions and tools, particularly automation and datapoints. Jason Kelly emphasized the potential of lab automation and AI integration as significant revenue opportunities, though he cautioned about the newness of this area.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer regarding the specific timeline or certainty of achieving general-purpose automation and its revenue impact. Additionally, while discussing biosecurity, Jason Kelly did not clearly address whether geopolitical tensions are a macro trend or anecdotal, leaving some ambiguity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI bioengineering
Accounting Officer
Biosecurity segment
CFO Coen
CFO Conference
CFO seat
CFO year
Cell Engineering
Chief Accounting
Coen Chief
Coen progress
Communications Ownership
Director Coen
ET evening
Engineering program
Founder CEO
Ginkgo Tools
Ginkgoresults
Manager Communications
Marshall Senior
Ownership Kelly
RD
Senior Manager
automation
bench
cost cutting
cost reduction
mix output
noncash item
output chef
segment loss
segment margin
set tool
share
slide axis
DNA Transcript
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call highlights a strategic focus on autonomous labs, a growing area with interest from key tech sectors, but lacks detailed financial performance data. The absence of revenue, margins, and cash flow information, combined with competition risks, tempers optimism. The market reaction is expected to be neutral, as excitement about innovation is balanced by uncertainties and competition.
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2025 Earnings Call Transcript
Positive2-27
The earnings call reveals improvements in financial metrics, including reduced operating losses and cash burn due to restructuring. Although revenue decreased, optimistic guidance and strategic initiatives in AI and robotics present potential growth avenues. The Q&A section highlights positive reception of new services and potential revenue tailwinds. However, management's vague response on U.S. onshoring introduces some uncertainty. Overall, the positive elements, such as improved financial health and strategic growth plans, outweigh negatives, suggesting a likely positive stock price movement.
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2025 Earnings Call Transcript
Unknown11-6
Despite strong cash reserves and cost management, the company faces challenges with declining revenues and increased losses in Cell Engineering. Positive aspects include restructuring efforts, optimism about government partnerships, and new product launches. However, the lack of significant revenue growth, increased operating losses, and the necessity to reset commitments with Google Cloud temper the outlook. The Q&A reveals optimism about AI and robotics, but the absence of immediate financial benefits suggests a neutral outlook for the stock price in the short term.
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed picture. While there are positives like improved EBITDA, cost reductions, and strong cash position, there are concerns about macroeconomic uncertainties, execution risks in new markets, and a reduction in biosecurity guidance. The Q&A section reveals potential in automation and RNA solutions but lacks clarity on timelines and geopolitical impacts. Overall, the mixed signals and lack of strong catalysts suggest a neutral stock price movement in the short term.
DNA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
